Thrombotic microangiopathy in HCV (+) renal allograft recipient

advertisement
Thrombotic microangiopathy
in HCV (+) renal allograft
recipient
Agnieszka Perkowska-Ptasinska
Transplantation Institute, Warsaw Medical University, Poland
HCV (+) male renal allograft recipient
• native kidneys’ function loss due to
nephroangiosclerosis at the age of 50,
• KTX at the age of 55,
• donor: cadaveric, female, age 45,
cause of death: multiple injuries due to a car
accident,
• post-TX
basic immunosuppression:
Pred + MMF + tac
• immediate graft function after KTX
4 weeks after KTX
• serum creatinine concentration elevation,
• platelet count, LDL, and haptoglobin levels:
within normal limits
→ kidney transplant biopsy:
- an acute vascular rejection (Banff IIA)
- mild thrombotic microangiopathy
- no C4d deposition.
First graft biopsy
(4 weeks after Tx)
The 1st graft biopsy
(4 weeks after Tx)
Further course
• good response to antirejection treatment
(steroid pulse therapy) with the decrease in
the serum creatinine concentration to the
pre-rejection value of 1,0 mg/dl,
• due to the biopsy findings: a change in the
IS regimen: ↓tac
 MMF exposure
A year after Tx
• proteinuria of 2,0 g/day,
• a rise in serum creatinine
concentration to 1,3 mg/dl.
A year after Tx
• Clinically: signs of intravascular coagulation (mildly
decreased platelet count, slightly elevated LDL and
decreased haptoglobin levels),
• no anti-HLA antibodies against class I and class II
antigens in the serum,
• further serological testing: anticardiolipin antibodies
in IgG class,
• HCV-PCR: high number of viral copies in patient’s
blood, but the liver function tests normal.
→
2nd graft biopsy
The 2nd biopsy
(a year after Tx)
• LM:
- acute lesions: thrombi in some of the glomerular capillaries
and arterioles,
- chronic lesions: double contouring of some of glomerular
capillaries, IFTA I, moderate arteriolar hyalinisation, arterial
intimal sclerotisation with mild reduction in vascular lumen,
- no C4d deposition in PTCs,
• the immunofluorescence: negative for Ig and complement
components.
• EM: electron-lucent expansion of the subendothelial zone
with the deposition of basement membrane/lamina densa-like
material.
The 2nd graft biopsy
(a year after Tx)
The 2nd graft biopsy
(a year after Tx)
FINAL
DIAGNOSIS
Chronic active thrombotic
microangiopathy, most probably due to
HCV-related presence of anticardiolipin
antibodies
Further course
• treatment: intravenous immunoglobulins and
plasmapheresis,
• response:
- decrease in the anticardiolipin antibodies level
- stabilization of renal function, and the level of
proteinuria,
• liver biopsy: mild chronic hepatitis with portal to
portal (Ishak’s stage 3 ) fibrosis
The patient is currently receiving antiviral therapy.
Thrombotic microangiopathy
after kidney transplantation
• relatively common lesion (affects about 20% of
kidney grafts recipients), may occur any time
after TX, although the risk seems to be higher
in the first 6 months after Tx,
• may be clinically silent or overt, limited to the
graft or widespread
Thrombotic microangiopathy
after kidney transplantation
Prognosis:
• depends on the etiopathogenesis of this process,
• is better in TMA localized to the graft,
• is better in cases limited to glomeruli
• depends on the intensity of lesions (both acute
and chronic): TMA may affect single arterioles
and/or glomeruli, it may be also widespread and
complicated by the focal infarcts of kidney
tissue,
Thrombotic microangiopathy
after kidney transplantation
Morphology of acute TMA:
• edematous widening of the subendothelium in
capillaries and arterioles,
• mucoid thickening of the arterial intima,
• the presence of fibrin and/or platelet
thrombi within the wall or in the vascular
lumen,
• red cell fragmentation and entrapment within
edematous vascular walls,
• focal fibrinoid necrosis of the vascular wall
(capillaries, arterioles, arteries),
• in glomeruli: thrombi, mesangiolysis, collapse
and wrinkling of GBM (acute ischemia)
Thrombotic microangiopathy
after kidney transplantation
Morphology of chronic TMA:
• glomeruli
– double contours of capillary walls,
- chronic ischemia of the tuft,
- secondary FSGS without immunological complexes in IF,
- in EM: thickening and reduplication of the glomerular
capillary basement membrane with cellular interposition,
• arteries
– sclerotisation of the intima, in the early phase without
the multiplication of the elastica,
• arterioles
– sclerotisation of the subendothelial region,
- hyalinisation.
Thrombotic microangiopathy
after kidney transplantation
Pathogenesis:
Two broad categories:
• the recurrence of TMA after Tx,
• TMA that evolves de novo after Tx.
The differentiation between the recurrent vs de novo TMA
is not possible on morphological grounds.
Thrombotic microangiopathy
after kidney transplantation
Recurrent TMA
• usually within the first year (sometimes first
days) after Tx,
• in majority of cases the recurrence of TMA leads
to the graft loss (70%)
(3-years graft survival ± 50%)
TMA recurrence after Tx –
risk factors
Types of common recurrences:
• the deficiency of factors I, B, H,
ADAMTS13 (vWF cleaving protease),
• the presence of Ab against complement components,
• antiphospholipid syndrome,
• idiopathic HUS,
• TMA in scleroderma,
Very rare recurrences:
• familial TMA caused by the deficiency of MCP and
thrombomodulin (both are transmembrane proteins),
• HUS associated with E.coli or S.dysenteriae infection
TMA recurrence after Tx –
risk factors
The risk of TMA recurrence:
• rises with older age of the disease presentation in native
kidneys,
• is higher in cases characterized by more dynamic evolution
of TMA-dependant ESKD in native kidneys,
• is higher in living-related donation,
• is higher in patients treated with CNI
TMA evolving de novo after KTX
– risk factors
• ischemia-reperfusion injury:
- stimulates endothelial apoptosis, and the release of prothrombotic
substances,
• CNI toxicity, mTOR inhibitors toxicity:
- direct injury to the endothelium,
- suppression of antithrombotic factor C activity,
- increased tissue thromboplastin and vWF multimers production,
• OKT3 toxicity (currently very rare complication):
- production of procoagulants by stimulated by OKT3 inflammatory
cells,
• acute graft rejection, especially ABMR:
- T-cell, DSA toxicity to the endothelium,
• viral infections:
- direct injurious effect of the influenza virus A, CMV, HCV, HHV6,
parvovirus),
- indirect effect of CMV, HIV, HBV and HCV through the stimulation
of anticardiolipin Ab production
Conclusions
• TMA is a relatively common complication after KTX,
• it may have diverse clinical manifestation, it may be
clinically silent,
• it may be a recurrent phenomenon, or it may evolve
de novo after Tx,
• it’s pathogenesis is complex, and rarely definable
solely upon the morphology of kidney graft biopsy,
• the differentiation of TMA etiology requires
additional diagnostic tools including serological
(DSA, antiphospholipid antibodies, complement
components) and virological testing
Download
Related flashcards

Orthopedics

21 cards

Hygiene

25 cards

Alternative medicine

24 cards

History of medicine

34 cards

Pulmonology

33 cards

Create Flashcards